Susquehanna Fundamental Investments’s Zevra Therapeutics ZVRA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-26,892	Closed	-$345K	–	1928
2021 Q2	$345K	Sell	26,892 -2,572	-9%	-$27.6K	0.01%	1314
2021 Q1	$271K	Buy	+29,464	New	+$257K	﹤0.01%	1321

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna Fundamental Investments's ZVRA Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Zevra Therapeutics (ZVRA) in Q3 2021, closing a stake of 26,892 shares — an estimated $345K sold.

Susquehanna Fundamental Investments first reported a position in ZVRA in Q1 2021 and held it in 2 quarters. The position peaked at $345K in Q2 2021. 71 funds tracked by Wall St. Rank hold ZVRA as of Q3 2021.

Susquehanna Fundamental Investments reported no remaining Zevra Therapeutics position as of Q3 2021 after selling out during the quarter.
Susquehanna Fundamental Investments sold 26,892 Zevra Therapeutics shares in Q3 2021, an estimated $345K.
Susquehanna Fundamental Investments first reported a position in Zevra Therapeutics in Q1 2021 and held it in 2 quarters.
Susquehanna Fundamental Investments's Zevra Therapeutics position peaked at $345K in Q2 2021.
71 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.